![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine; and the Division of Clinical Pharmacology, Tufts-New England Medical Center, Boston, Massachusetts
Midazolam, triazolam (TRZ), testosterone, and nifedipine have all been widely used as probes for in vitro metabolism of CYP3A. We used these four substrates to assess the contributions of CYP3A4 and CYP3A5 to in vitro biotransformation in human liver microsomes (HLMs) and in recombinant enzymes. Recombinant CYP3A4 and CYP3A5 (rCYP3A4 and rCYP3A5) both produced 1-OH and 4-OH metabolites from midazolam and triazolam, 6ß-hydroxytestosterone from testosterone, and oxidized nifedipine from nifedipine. Overall, the metabolic activity of CYP3A5 was less than that of CYP3A4. Ketoconazole potently inhibited midazolam, triazolam, testosterone, and nifedipine metabolite formation in HLMs and in rCYP3A4. The inhibitory potency of ketoconazole in rCYP3A5 was about 5- to 19-fold less than rCYP3A4 for all four substrates. In testosterone interaction studies, testosterone inhibited 1-OH-TRZ formation, but significantly activated 4-OH-TRZ formation in HLMs and rCYP3A4 but not in rCYP3A5. Oxidized nifedipine formation was inhibited by testosterone in rCYP3A4. However, in rCYP3A5, testosterone slightly activated oxidized nifedipine formation at lower concentrations, followed by inhibition. Thus, CYP3A4 and CYP3A5 both contribute to midazolam, triazolam, testosterone, and nifedipine biotransformation in HLMs, with CYP3A5 being metabolically less active than CYP3A4 in general. Because the inhibitory potency of ketoconazole in rCYP3A5 is substantially less than in rCYP3A4 and HLMs, CYP3A5 is probably less important than CYP3A4 in drug-drug interactions involving ketoconazole and CYP3A substrates.
This article has been cited by other articles:
|
|
 |
|
  J. B. Dennison, M. A. Mohutsky, R. J. Barbuch, S. A. Wrighton, and S. D. Hall Apparent High CYP3A5 Expression Is Required for Significant Metabolism of Vincristine by Human Cryopreserved Hepatocytes J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 248 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Volak, S. Ghirmai, J. R. Cashman, and M. H. Court Curcuminoids Inhibit Multiple Human Cytochromes P450, UDP-Glucuronosyltransferase, and Sulfotransferase Enzymes, whereas Piperine Is a Relatively Selective CYP3A4 Inhibitor Drug Metab. Dispos., August 1, 2008; 36(8): 1594 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Ku, H.-J. Ahn, K.-A. Seo, H. Kim, M. Oh, S. K. Bae, J.-G. Shin, J.-H. Shon, and K.-H. Liu The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil Drug Metab. Dispos., June 1, 2008; 36(6): 986 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I. Somers, N. Lindsay, B. M. Lowdon, A. E. Jones, C. Freathy, S. Ho, A. J. M. Woodrooffe, M. K. Bayliss, and G. R. Manchee A Comparison of the Expression and Metabolizing Activities of Phase I and II Enzymes in Freshly Isolated Human Lung Parenchymal Cells and Cryopreserved Human Hepatocytes Drug Metab. Dispos., October 1, 2007; 35(10): 1797 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Yoon, K.-B. Kim, H. Kim, K.-A. Seo, H.-S. Kim, I.-J. Cha, E.-Y. Kim, K.-H. Liu, and J.-G. Shin Characterization of Benidipine and Its Enantiomers' Metabolism by Human Liver Cytochrome P450 Enzymes Drug Metab. Dispos., September 1, 2007; 35(9): 1518 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ma, S. L. Polsky-Fisher, S. Vickers, D. Cui, and A. D. Rodrigues Cytochrome P450 3A-Dependent Metabolism of a Potent and Selective {gamma}-Aminobutyric AcidA{alpha}2/3 Receptor Agonist in Vitro: Involvement of Cytochrome P450 3A5 Displaying Biphasic Kinetics Drug Metab. Dispos., August 1, 2007; 35(8): 1301 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Dennison, D. R. Jones, J. L. Renbarger, and S. D. Hall Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 553 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Picard, N. Djebli, F.-L. Sauvage, and P. Marquet Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5 Drug Metab. Dispos., March 1, 2007; 35(3): 350 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. He, M. H. Court, D. J. Greenblatt, and L. L. von Moltke Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity. J. Clin. Pharmacol., November 1, 2006; 46(11): 1356 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Campbell, C. K. Stroud, M. T. Nakamura, M. A. Lila, and J. W. Erdman Jr. Serum Testosterone Is Reduced Following Short-Term Phytofluene, Lycopene, or Tomato Powder Consumption in F344 Rats J. Nutr., November 1, 2006; 136(11): 2813 - 2819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Carr, R. Norcross, Y. Fang, P. Lu, A. D. Rodrigues, M. Shou, T. Rushmore, and C. Booth-Genthe Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant Enzymes Drug Metab. Dispos., October 1, 2006; 34(10): 1703 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Dennison, P. Kulanthaivel, R. J. Barbuch, J. L. Renbarger, W. J. Ehlhardt, and S. D. Hall SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5 Drug Metab. Dispos., August 1, 2006; 34(8): 1317 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. He, M. H. Court, D. J. Greenblatt, and L. L. von Moltke FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., July 1, 2006; 34(7): 1198 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Suh, B.-K. Koo, S.-Y. Zhang, K.-W. Park, J.-Y. Cho, I.-J. Jang, D.-S. Lee, D.-W. Sohn, M.-M. Lee, and H.-S. Kim Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel Can. Med. Assoc. J., June 6, 2006; 174(12): 1715 - 1722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Lee, W. J. Jusko, C. G. Salaita, K. A. Calis, M. W. Jann, V. E. Spratlin, J. A. Goldstein, and Y. Y. Hon Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated With CYP3A5*3 Allele or a Change in Diet Composition. J. Clin. Pharmacol., May 1, 2006; 46(5): 515 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hallifax, H. C. Rawden, N. Hakooz, and J. B. Houston PREDICTION OF METABOLIC CLEARANCE USING CRYOPRESERVED HUMAN HEPATOCYTES: KINETIC CHARACTERISTICS FOR FIVE BENZODIAZEPINES Drug Metab. Dispos., December 1, 2005; 33(12): 1852 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Mathews, A. S. Etheridge, J. L. Valentine, S. R. Black, D. P. Coleman, P. Patel, J. So, and L. T. Burka PHARMACOKINETICS AND DISPOSITION OF THE KAVALACTONE KAWAIN: INTERACTION WITH KAVA EXTRACT AND KAVALACTONES IN VIVO AND IN VITRO Drug Metab. Dispos., October 1, 2005; 33(10): 1555 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Klees, P. Sheffels, O. Dale, and E. D. Kharasch METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES Drug Metab. Dispos., March 1, 2005; 33(3): 303 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Galetin, C. Brown, D. Hallifax, K. Ito, and J. B. Houston UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES Drug Metab. Dispos., December 1, 2004; 32(12): 1411 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Huang, Y. S. Lin, D. J. McConn II, J. C. Calamia, R. A. Totah, N. Isoherranen, M. Glodowski, and K. E. Thummel EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM Drug Metab. Dispos., December 1, 2004; 32(12): 1434 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Paine, A. B. Criss, and P. B. Watkins TWO MAJOR GRAPEFRUIT JUICE COMPONENTS DIFFER IN INTESTINAL CYP3A4 INHIBITION KINETIC AND BINDING PROPERTIES Drug Metab. Dispos., October 1, 2004; 32(10): 1146 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Vanden Bossche, J. Ausma, H. Bohets, K. Vermuyten, G. Willemsens, P. Marichal, L. Meerpoel, F. Odds, and M. Borgers The Novel Azole R126638 Is a Selective Inhibitor of Ergosterol Synthesis in Candida albicans, Trichophyton spp., and Microsporum canis Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3272 - 3278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Warrington, D. J. Greenblatt, and L. L. von Moltke Age-Related Differences in CYP3A Expression and Activity in the Rat Liver, Intestine, and Kidney J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 720 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Patki, L. L. von Moltke, J. S. Harmatz, L. M. Hesse, M. H. Court, and D. J. Greenblatt Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 874 - 879. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
